by Payash Bahuguna | Jun 21, 2022 | PR
Iktos today announced a research collaboration with Zealand Pharma A/S, a biotechnology company changing lives with innovative peptide-based medicines to co-develop generative and predictive AI technologies for peptide drug design. Follow the link for the full press...
by Payash Bahuguna | May 10, 2022 | PR
Iktos and Sygnature Discovery announce their collaboration in Artificial Intelligence for de novo drug design. Under the 3-year agreement, Sygnature will deploy Iktos’s de novo generative design software Makya™, which will be used by Sygnature scientists to...
by Payash Bahuguna | Apr 5, 2022 | PR
Iktos and Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business that provides comprehensive healthcare services to improve the quality of life, announce a strategic collaboration agreement in Artificial Intelligence for new drug design....
by Payash Bahuguna | Jan 5, 2022 | PR
Iktos and Astrogen have entered into a research collaboration agreement aimed at discovery of innovative small molecule pre-clinical drug candidates for Parkinson’s disease. Follow the link for the full press...
by Payash Bahuguna | Dec 25, 2021 | PR
Under the agreement, Iktos will apply its de novo ligand and structure-based generative modeling technologies, its AI-based retrosynthesis analysis and planning tool Spaya™, and know-how complementing DDU’s drug discovery capabilities to expedite the identification of...
by Payash Bahuguna | Dec 8, 2021 | PR
Iktos announces deployment of our AI for drug design software Makya™ by Jiangsu Hengrui Pharmaceuticals Co., Ltd. Follow the link for the full press...
